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Abstract
Background: Disease-specific quality of life (QoL) measures have enhanced the capacity of outcome measures
to evaluate subtle changes and differences between groups. However, when the specific disease is rare, the cohort
of patients is small and international collaboration is often necessary to accomplish meaningful research. As many
of the QoL measures have been developed in North American English, they require translation to ensure their
usefulness in a multi-cultural and/or international society. Published guidelines provide formal methods to achieve
cross-culturally comparable versions of a QoL tool. However, these guidelines describe a rigorous process that
is not always feasible, particularly in rare disease groups. The objective of this manuscript is to describe the
process that was developed to achieve accurate cross-cultural translations of a disease-specific QoL measure, to
overcome the challenges of a small sample size, i.e. children with a rare disorder.
Procedure: A measurement study was conducted in the United Kingdom (UK), France, Germany and Uruguay,
during which the validated measure was translated into the languages of the respective countries.
Results: This is a report of a modified, child-centric, cross-cultural translation and adaptation process in which
culturally appropriate and methodologically valid translations of a disease-specific QoL measure, the Kids' ITP
Tools (KIT), were performed in children with immune thrombocytopenic purpura (ITP). The KIT was translated
from North American English into UK English, French, German, and Spanish.
Conclusion: This study was a successful international collaboration. The modified process through which
culturally appropriate and methodologically valid translations of QoL measures may be achieved in a pediatric
population with a relatively rare disorder is reported.
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Introduction
The development of quality of life (QoL) measures has
greatly enhanced the scope of outcomes that can now be
measured by rigorous scientific methods. Their inclusion
in clinical studies enables the assessment of differences
and subtle changes between groups, either due to time or
treatment, which was not previously possible. Changes in
QoL are particularly salient to children and their families.
As the cohort of patients with any rare disorder is small
and even smaller when the focus is specifically children,
international collaboration in the research of such disor-
ders is essential as we work towards evidence-based prac-
tice. Consequently, it is recognised that QoL measures,
many of which have been developed in North American
English, require translation in order to retain their validity
and reliability in a multi-cultural society and internation-
ally.
In order to achieve accurate, cross-culturally comparable
versions, formal methods of translation and adaptation
need to be applied. This process involves both linguistic
translation where the measure is literally translated into
the new language and cultural translation where it is
adjusted appropriately for the cultural context, as well as
an evaluation process to ensure comparability with the
original tool. Several publications have outlined processes
for achieving this cross-cultural adaptation. Guillemin et
al published a report in 1993, in which recommendations
were proposed based on their review of the literature[1].
This was followed by two publications outlining guide-
lines for a comprehensive process of cross-cultural adap-
tation[2,3]. These guidelines and recommendations
require the inclusion of large numbers of subjects across
several countries and extensive use of professional transla-
tors. The recommendations from the published guide-
lines are summarized in Table 1 along with the modified
process that is described in this report. Although these
guidelines provide an excellent frame of reference, they
are based on expert opinion. The best method to use is not
clear. Furthermore, while these guidelines may be applica-
ble when translating and adapting measures for large
cohorts of adults, the process presents unique challenges
when applied to children, and particularly when the
measure is being developed for use in children with a rare
disorder. Examples of such challenges include: 1) the dif-
ficulty in applying the guidelines to a small sample size
(<50 subjects), and 2) the specific needs of children,
including their unique linguistic style, which is difficult
for professional translators to capture.
To determine what was actually practiced in the field of
measurement in the pediatric medical literature, we con-
ducted a review of the literature from 1993 (when the first
guidelines were published in the Journal of Clinical Epi-
demiology) to 2007. We identified 42 publications (birth
to 12 years of age, 'validate' or 'validation' as a text word
and Quality of Life exploded as a MESH term and cross-
cultural comparison as a MESH term). Most of the publi-
cations were focused on generic measures, or measures
that are applicable to large populations (e.g., asthma or
arthritis). The fact that only one report was relevant to a
rare condition, hemophilia,[4] underscores the barriers to
cross-cultural translation in rare conditions.
The development of measures that can be used in multi-
national studies is essential, particularly in rare disorders
in children, since it is international collaboration that will
enable new treatment interventions for rare disorders to
be fully evaluated. Without cross-culturally validated
measures, quality of life will be eliminated from such
studies. However, the rigorous process described to date
may prevent cross-cultural adaptations of questionnaires
that are required in multilingual and multi-cultural
research. Alternatively, some researchers may elect to
implement QoL measures on which forward and back-
ward translations have been performed, but that have not
been tested with children, due to the constraints of a small
sample size (for example, the Greek version of the Ped-
sQL, http://www.pedsql.org). Therefore, we propose a
modified cross-cultural translation process for disease-
specific pediatric QoL measures that is practical in the
context of small sample sizes, yet is potentially capable of
achieving the same high quality standards as have been
previously published. The purpose of this report is to
describe a process through which culturally appropriate
and methodologically valid translations and adaptations
of QoL measures may be achieved in a pediatric popula-
tion with a relatively rare disorder, childhood immune
thrombocytopenic purpura (ITP).
Methods
We developed a modified process for cross-cultural trans-
lation and adaptation that factored into account the chal-
lenges of small sample size in rare disorders, and applied
it to a quality of life tool. We used the KIT (Kids' ITP
Tools), a disease-specific health-related QoL measure
developed for children with ITP, originally developed and
validated in North American English, as the example. This
tool consists of three related measures: a child self-report,
a parent report of their child's quality of life (proxy), and
a parent-impact report[5]. The KIT was cross-culturally
translated and adapted for use in the United Kingdom
(UK), France, Germany, and Uruguay. Our approach fol-
lowed previously published principles [2] and included
five steps: 1) forward translation, 2) backward translation,
3) review of source and final translated version, 4) pre-
testing for equivalence in source and final documents in
the format of cognitive debriefing, and 5) an international
consensus meeting. This process is presented in Figure 1.Health and Quality of Life Outcomes 2009, 7:92 http://www.hqlo.com/content/7/1/92
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Table 1: A comparison of cross-cultural adaptations of quality of life measures.
Guillemin et al 1993 [1] Bullinger et al 1998 [3] Beaton et al 2002 [2] Modified process for 
KIT
Background and 
methods
Linguistic translation alone 
is insufficient for cross-
cultural application of 
measures.
International Society for 
Quality of Life Assessment 
project group 
recommendations.
Based on Guillemin et al 
1993.
Published guidelines too 
rigorous for a small cohort 
of children with a rare 
disease.
Systematic literature 
review of the methodology 
of cross-cultural 
adaptation.
Focused primarily on the 
SF36, EORTC and 
Nottingham Health Profile 
experiences.
Guidelines Currently Used 
by the American Academy 
of Orthopedic Surgeons 
Outcomes Committee.
Proposed standardized 
guide-lines based on the 
review.
Forward translation ≥ 2 Professional translators 
NSTL* and culturally 
representative.
≥ 2 Professional translators 
NSTL.
2 Professional translators 
(NSTL).
Single forward translation 
by bilingual clinical expert 
in target country.
Both naive and informed 
translators are required.
Translators naïve to SF36. Both naive and informed 
translators are required.
≥ 2 Independent 
translations.
Translators NSTL rate the 
difficulty of the translation.
2 Independent translations.
Consensus after 
forward translation
No specific process 
outlined.
Within-country 
reconciliation of 
problematic items and 
response options with local 
PI and translators.
2 Translators and a 
facilitator synthesize a 
translated version of the 
questionnaire from the 2 
forward translations.
Not part of the process.
Back translation(final 
language into source 
language)
≥ 2 Professional, naïve 
translators NSE.#
2 Professional translators 
NSE.
2 Professional, naïve 
translators NSE.
1 Professional, naïve 
translator for each of the 
target languages.
Translate independently. Health Assessment Lab 
compared back translations 
to initial version for 
"conceptual equivalence." 
Discrepancies discussed 
with local PI.
Translators should not 
have a clinical background.
Single back translation.
Must have as many back 
translations as forward 
translations.
Must have as many back as 
forward translations.
Consensus/Synthesis A multi-disciplinary 
committee including, 
experts in concepts and 
the disease, to compare 
English versions.
International investigators 
meeting.
Expert committee 
consolidates all translations 
and produces a 
questionnaire for field-
testing.
A multi-disciplinary expert 
committee compares 
English back-translated 
versions.
Structured techniques are 
used to resolve 
discrepancies.
Expert committee consists 
of methodologists, health 
care professionals, language 
experts and translators.
Local bilingual clinical 
expert adjudicates any 
discrepancies with 
committee.
Inclusion of bilingual 
members is ideal.
Consensus meeting to 
form reconciled versions.
Testing with 
participants
The translated 
questionnaire may be 
administered to a group of 
patients using a probe 
technique.
Focus groups with up to 50 
respondents and 
translations revised as 
needed.
The translated version is 
administered to 30-40 
people using a probe 
technique.
Training provided for 
cognitive debriefing skills 
by operations group.
or Testing done in individual 
countries.
Cognitive debriefing in 
individual countries.
Both the English and 
translated questionnaires 
are administered to 
bilingual lay people.
Modified EORTC 
debriefing questionnaire 
used.Health and Quality of Life Outcomes 2009, 7:92 http://www.hqlo.com/content/7/1/92
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Step 1: Forward translation
A bilingual clinical expert, defined as a health care profes-
sional with clinical expertise in childhood ITP, in each of
the target countries (UK, France, Germany, Uruguay) and
who was also a native speaker of the target language trans-
lated the source document (North American-English KIT)
into the target language, i.e. UK English, French, German
or Spanish.
Step 2: Backward Translation
A qualified professional translator (affiliated with a com-
mercial translating service in Canada) performed a single
backward translation into the original language, for each
of the three target languages excluding UK English. The
commercial translating service in Canada retains the serv-
ices of international translators which ensured that the
translations were completed in their natural milieu. The
translators were also naïve to the objectives of the transla-
tion.
Step 3: Review of source and translated version
A committee from the Canadian co-ordinating centre was
formed to oversee the cross-cultural translation process at
all four sites. The committee consisted of experts in the
disease (ITP) as well as experts in the intent and content
of the measure and the measure's development. A mem-
ber of the committee (CC) compared the source docu-
ment to each of the back translations and highlighted any
differences. A bilingual health care professional with clin-
ical expertise in the management of childhood ITP (an
academic pediatric hematologist), whose mother tongue
was the official language of the target country and who
was not involved in steps 1 and 2, assisted the committee
by adjudicating any discrepancies. The final adjudication
process was conducted via teleconference with the clinical
expert who had performed the forward translation in each
of the target countries, the bilingual clinical expert from
Canada and the study operations team. Consensus was
met to create a reconciled version of the translated docu-
ment.
Step 4: Pre-testing
To ensure equivalence in linguistic, cultural and clinical
context, cognitive debriefing was conducted in each of the
countries following the methods described by Jobe[6].
The clinical experts from each of the countries identified a
person who could perform the cognitive debriefings. The
debriefers were fluent in their local language and dialect
as well as fluent in English (written and spoken). The
Canadian operations team met with the site leaders and
cognitive debriefers from all of the countries, to deliver
formal training and conduct practice training sessions in
cognitive debriefing. Each of the 4 cognitive debriefers
were expected to debrief at least 10 children (7 to 18 years
of age), and 10 parents (some of whom represented chil-
dren less than 7 years of age) in their home country. The
children, who were invited to participate by each center,
had either acute or chronic ITP and were willing to take
part in the cognitive debriefing phase of the process of
cross-cultural translation.
During each debriefing, the debriefer recorded whether or
not each of the items was reported to be problematic in
terms of the comprehension of the concept, the wording
of the question, or the response options. They also
recorded the response selected and any suggestions for
improvements made by the respondents (e.g. more
appropriate vocabulary). After at least three debriefings
Total number of formal 
translations
At least 2 forward and 2 
back translations.
At least 2 forward 
translations and a 
consensus version, i.e. 3.
At least 2 forward 
translations and consensus 
version, i.e. 3.
Single forward and back 
translation.
2 Back translations. At least 2 back translations.
Number of consensus 
meetings
After forward and back 
translations.
Between forward and back 
translations.
Between forward and back 
translations.
After forward and back 
translations.
After pre-testing. After difficulty ratings. After back translations. After pre-testing.
After back translation.
Role of patients To ensure face validity of 
the translation.
Lay panel made up of 
general public was used to 
achieve consensus when 
translators could not.
To ensure translated 
version retains equivalence 
to original version.
To ensure face validity of 
the translation.
Patients and lay people 
pilot tested final forward 
translation.
Number of patients Specific requirement is not 
Stipulated.
50 30-40 10 Children and their 
parents per country.
* NSTL = Native speakers of target language # NSE = Native speakers of English
Table 1: A comparison of cross-cultural adaptations of quality of life measures. (Continued)Health and Quality of Life Outcomes 2009, 7:92 http://www.hqlo.com/content/7/1/92
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The cross-cultural translation process of the KIT Figure 1
The cross-cultural translation process of the KIT.Health and Quality of Life Outcomes 2009, 7:92 http://www.hqlo.com/content/7/1/92
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were completed, the local Canadian committee met via
teleconference with the local clinical expert, and the cog-
nitive debriefer in each of the target countries. The data
collected were reviewed, any concerns that arose during
the debriefing process were discussed and potential solu-
tions were recommended. After consensus was reached,
the agreed changes were implemented and used in the
ensuing cognitive debriefings. This process was repeated
until no new information emerged. The data collected by
each of the cognitive debriefers were analysed by the
Canadian co-ordinating team to identify items in which
>10% of children or >10% of parents in any country
reported difficulties. We postulated that the cognitive
debriefing of 10 children and 10 parents would be suffi-
cient for the pre-testing phase of the cross-cultural transla-
tion process.
Step 5: International Consensus Group Meeting
Finally, the entire group (Canadian operations team as
well as the teams from UK, Germany and Uruguay) met at
an international consensus meeting. The items that were
identified as needing revision during the cognitive
debriefing process in each of the four countries were dis-
cussed along with potential solutions, and collective deci-
sions were made. These decisions established the final
version of the measure for each of the target countries.
Results
The process of forward translation, backwards translation
and cognitive debriefing was conducted for the three
related measures (child version, parent-proxy version and
parent-impact version) in four countries over 10 months.
In total, eight clinical experts (four from the Canadian
operations team and one from each of the target coun-
tries), three professional translators (one each for French,
German and Spanish) and four cognitive debriefers (one
each from UK, France, Germany and Uruguay), 39 chil-
dren with ITP and 67 parent-child pairs participated. The
mean age of the complete sample of children was 10.2
years (range 5-15 years). Of the 39 children who provided
data (i.e. completed the child version), the mean age was
11.9 years (range 7-17 years) and the male-female ratio
was 1:1.9. Twelve children with acute ITP and 27 children
with chronic ITP were included.
Table 2 demonstrates the proportion of respondents iden-
tifying areas of concern in the newly translated KIT. Over-
all, 69% of children identified some areas for
improvement in the child version of the KIT, 39% of par-
ents identified some areas of question in the proxy version
of the KIT, and 69% of parents identified some questions
to be changed in the parent-QoL measure. Changes were
suggested for 10 of the 26 KIT items: seven were identified
only by children, one was identified only by parents and
two were identified by both children and parent proxies.
It became apparent that the problematic items were con-
sistent between the child and proxy version and 8 of the
10 problems were identified in two or more countries.
Changes were also suggested for 9 of the 26 parent-KIT
items; eight of these were identified by parents in two or
more countries. Problems encountered in achieving cross-
cultural equivalence included discrepancies in semantic
equivalence (vocabulary and grammar), idiomatic equiv-
alence (idioms and colloquialisms) and conceptual
equivalence (disease-related). An example of a difference
in semantics was the statement "I felt sick," referring to
feeling "unwell," which was interpreted by UK patients, as
"I felt nauseated." An example of a substitution to achieve
idiomatic equivalence was the word "cranky," a North
American colloquialism that was translated into "bad
tempered/moody" in UK English, "bizarre" in French,
"genervt" in German and "irritable" in Spanish. An exam-
ple of conceptual equivalence was found in the concept of
receiving "treatment through an IV" and "taking medicine
by mouth," which was foreign to UK, French and German
patients, as they are not commonly treated with medica-
tion when thrombocytopenic. Furthermore, "staying
overnight in hospital" was the norm for patients inter-
viewed in Uruguay, but this was not a common practice
for patients in the UK, France and Germany.
Common semantic issues also arose with respect to the
response options. The response "seldom" translated dif-
ferently in each country and was often back translated to
"rarely." For example, when "seldom" was translated into
French it became 'rarement,' in Spanish it became "rare-
mente," and in German it became "selten". All three of
these words were back translated to "rarely." The UK
group identified concerns with the comprehension of
"seldom" after their third cognitive debriefing and elected
to change "seldom" to "rarely" in the UK version.
After an international consensus meeting, consensus was
met to institute changes to the questionnaires to achieve
improved linguistic and cultural translations. The
Table 2: Proportion of respondents identifying problems in the 
KIT
Country Children Proxy Parents
France 60% (9/15) 29% (6/21) 54% (13/24)
Germany 80% (4/5) 50% (6/12) 100% (12/12)
UK 100% (7/7) 73% (8/11) 64% (7/11)
Uruguay 58% (7/12) 25% (5/20) 70% (14/20)
TOTAL 69% (27/39) 39% (25/64) 69% (46/67)Health and Quality of Life Outcomes 2009, 7:92 http://www.hqlo.com/content/7/1/92
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response option "seldom" was changed to "rarely" in all
translations, except the German and North American-Eng-
lish questionnaires, as the cognitive debriefing had con-
firmed that "seldom" was understood by the children and
parents in these countries.
Three changes were made to the parent-impact version: 1)
the word "bother" was changed to "worry" in all of the
translations, 2) the phrase "did the uncertainty about"
was changed to "did not knowing about" in the UK ver-
sion, and 3) "note, you may provide other comments
about your child's ITP at the end of the questionnaire"
was added to all versions. The unit of measurement in
which a platelet count is reported was changed to reflect
each country's standard. In the UK-English version "IV"
was changed to "drip."
Discussion
We developed a modified process for the cross-cultural
translation of a quality of life tool that takes into account
the challenges of small sample size in a relatively rare dis-
order, namely ITP, occurring during childhood. The
method we developed is a simplified form of the rigorous
process for translation of measures, outlined in previously
published guidelines [1-3].
A single forward and back translation was performed for
each of the target languages in contrast to the guidelines
that suggest at least two of each translation is performed.
Bilingual clinical experts from each of the countries (pedi-
atric academic hematologists) completed the forward
translations, while professional translators were used for
the back translations. Our method required a local aca-
demic pediatric hematologist, fluent in the source and tar-
get languages, to participate in a teleconference to
facilitate the reconciliation process. We found the role of
the clinical experts to be essential to the process for several
reasons: they are pediatricians who by definition are
experts in child development and therefore helpful in
achieving age-appropriate translations, as well as under-
standing the specialized terminology used in disease-spe-
cific measures. The clinician in the target country, together
with his/her counterpart in Canada, further assisted the
process by identifying linguistically correct translations
that needed to be modified to achieve accurate, culturally
acceptable translation, e.g. "klinik" vs "poliklinik" in Ger-
man. This process identified that not only were accurate
child-centric linguistic and cultural translations required,
but in fact a medical/clinical translation was also neces-
sary. An example of this can be found in the short form
"IV," which is a North American abbreviation for "intrave-
nous catheter." The equivalent word for IV is "drip" in the
UK, and there was not a direct translation for this in
French. The inclusion of the clinical experts in our trans-
lation process provided the necessary detail, and replaced
the need for multiple forward and back translations and a
second commercial translator.
The cognitive debriefing process identified important lin-
guistic and cultural issues, many of which were specific to
children. We believe that these nuances would have been
challenging for a professional commercial translator to
identify and this again underscores the role of the bilin-
gual clinical experts as part of the Canadian operations
team. Most of the issues were resolved by regular telecon-
ferences between the operations team and the investiga-
tors in the target country. The local bilingual clinical
experts participated in relevant meetings/teleconferences
to assist with translation, ensure accuracy and avoid any
misunderstandings. Changes were made after consensus
was met regarding an issue and were incorporated in the
ensuing debriefings. This process provided continued sur-
veillance of the linguistic/cultural/medical translation.
Any remaining issues were resolved at an international
consensus meeting. The result was four versions of the KIT
(comprised of the child, parent-proxy and parent-impact
versions) with linguistically, culturally and clinically
appropriate modifications.
Through this process we identified a third aspect of trans-
lation. Translation into the new clinical context was essen-
tial, in addition to the linguistic and cultural translations.
The management of childhood ITP differs from country to
country, therefore the process had to include the appro-
priate translation of terminology to accommodate the dif-
ferent approaches to the management of childhood ITP.
An example of this is that the majority of children diag-
nosed with ITP in the UK would be observed only,
whereas many of these children in North America would
receive active treatment. Although the translated KITs
have not been validated yet, we believe that despite the
different treatment approaches, the same QoL tool will be
used and understood by all patients.
There is no evidence that any one of the previously pub-
lished guidelines is superior and as suggested by Perneger
et al "more empirical research is needed to understand
what translation methods yield the best results."[7] A sim-
ple linguistic translation may not provide an accurate
translation process. We identified two key problems with
the published guidelines during the cross-cultural transla-
tion of the KIT. First, our cohort of patients was smaller
than the 30-50 patients suggested in the guidelines. As ITP
is a rare disorder in childhood, it would be unrealistic to
assume such a large cohort. Secondly, the specific linguis-
tic styles of children may have been lost during the trans-
lation process by commercial translators. In this regard,
we believe the roles of the bilingual clinical experts to be
imperative. These experts ensured accurate linguistic and
cultural translations and avoided the need for at least twoPublish with BioMed Central    and   every 
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forward and back translations as per the published guide-
lines. A modified linguistic translation with cultural adap-
tation may represent an achievable process, which is a
compromise between a simple linguistic translation and
the standard provided by the published guidelines. We
believe that this modified, child-centric approach to the
cross-cultural translation of the KIT will prove to be as
accurate as the processes previously published. This suc-
cessful international collaboration has resulted in the
adapted process proposed here being used as a guide for
similar studies. The common measure that resulted from
this process has undergone validation and will be
reported.
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